Delving into the Latest Updates on SBI-183 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

Arizona State University

Mayo Clinic

Skysong Innovations

Active Organization-

Inactive Organization

Sapphire Biotech, Inc.Startup

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Author: Bobkov, Andrey ; Mukhopadhyay, Debabrata ; Ho, Thai H. ; Dutta, Shamit K. ; Hanavan, Paul D. ; Sergienko, Eduard ; Lake, Douglas F. ; Meurice, Nathalie ; Castle, Erik P. ; Polito, Alysia ; Faigel, Douglas O. ; Copland, John A. ; Luo, Huijun ; Petit, Joachim L. ; Caulfield, Thomas R. ; Pal, Krishnendu ; Fifield, Amber L.

AbstractQuiescin sulfhydryl oxidase 1 (QSOX1) is an enzyme overexpressed by many different tumor types. QSOX1 catalyzes the formation of disulfide bonds in proteins. Because short hairpin knockdowns (KD) of QSOX1 have been shown to suppress tumor growth and invasion in vitro and in vivo, we hypothesized that chemical compounds inhibiting QSOX1 enzymatic activity would also suppress tumor growth, invasion, and metastasis. High throughput screening using a QSOX1-based enzymatic assay revealed multiple potential QSOX1 inhibitors. One of the inhibitors, known as “SBI-183,” suppresses tumor cell growth in a Matrigel-based spheroid assay and inhibits invasion in a modified Boyden chamber, but does not affect viability of nonmalignant cells. Oral administration of SBI-183 inhibits tumor growth in 2 independent human xenograft mouse models of renal cell carcinoma. We conclude that SBI-183 warrants further exploration as a useful tool for understanding QSOX1 biology and as a potential novel anticancer agent in tumors that overexpress QSOX1.

100 Deals associated with SBI-183

Login to view more data